APOE and Anxiety: During the different phases of clinical trials, Bapineuzumab showed mild to moderate adverse events, such as headache, back pain, anxiety, and fatigue, but also more severe ones, with vasogenic edema reported in both APOE ε4 and non-APOE ε4 patients [58].